Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$2.08 USD
-0.12 (-5.45%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $2.06 -0.02 (-0.96%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.08 USD
-0.12 (-5.45%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $2.06 -0.02 (-0.96%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
New Strong Buy Stocks for January 25th
by Zacks Equity Research
S, ASAN, PRLD, EMKR and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 25, 2023.
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
by Zacks Equity Research
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
by Zacks Equity Research
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
by Zacks Equity Research
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 169.5% in Prelude Therapeutics Incorporated (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prelude Therapeutics (PRLD) Enters Oversold Territory
by Zacks Equity Research
Prelude Therapeutics (PRLD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.